[Progress in development of new antischistosomal drugs in recent years].

Abstract

It is estimated that 200 million people have suffered the infection with schistosomes in the world. The fact that treatment of schistosomiasis only relies on a single drug praziquantel does not adapt to the demand. Although praziquantel exhibits excellent therapeutic efficacy, it shows no preventive action to the infection. Therefore, development of new anti-schistosomal drugs has been received serious attention. In this paper the recent development of new antischistosomal drugs such as oxadiazole-2-oxides, mefloquine, etc. has been reviewed, and the process of their development and anti-schistosomal properties recounted.

• Authors: Shu-Hua Xiao
• Journal: Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases (Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi) Vol. 28 Issue 3 Pg. 218-25 (Jun 30 2010) ISSN: 1000-7423 [Print] China
• PMID: 20806509 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Oxadiazoles
• Schistosomicides
• Praziquantel
• Mefloquine

Topics

• Animals
• Mefloquine (pharmacology)
• Oxadiazoles (pharmacology)
• Praziquantel (pharmacology)
• Schistosoma (drug effects)
• Schistosomicides